A phase 1 trial design exploring cell replacement therapy in people with Huntington’s disease

Takeaway

  • This phase 1 trial is designed to assess the safety and feasibility of cell replacement therapy (CRT) for people with Huntington’s disease (HD), whilst also exploring methodological issues for informing future trial design.

Why this matters

    There are no therapeutics to cure HD; however, CRT may halt disease progression as it could potentially re-establish some degree of normal neural circuitry.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.